FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180625801> ?p ?o ?g. }

• W3180625801 endingPage "1887" @default.
• W3180625801 startingPage "1873" @default.
• W3180625801 abstract "Therapy with nucleic acid polymers (NAPs), tenofovir disoproxil fumarate (TDF), and pegylated interferon (pegIFN) achieve high rates of HBsAg loss/seroconversion and functional cure in chronic hepatitis B virus (HBV) infection. The role of hepatitis B surface antigen (HBsAg) seroconversion and inactivation of covalently closed circular DNA (cccDNA) in establishing functional cure were examined. Archived serum from the REP 401 study was analyzed using the Abbott ARCHITECT HBsAg NEXT assay (Chicago, IL), Abbott research use-only assays for HBsAg immune complexes (HBsAg ICs), circulating HBV RNA, and the Fujirebio assay for hepatitis B core-related antigen (HBcrAg; Malvern, PA). HBsAg became < 0.005 IU/mL in 23 participants during NAP exposure, which persisted in all participants with functional cure. HBsAg IC declined during lead-in TDF monotherapy and correlated with minor declines in HBsAg. Following the addition of NAPs and pegIFN, minor HBsAg IC increases (n = 13) or flares (n = 2) during therapy were not correlated with HBsAg decline, hepatitis B surface antibody (anti-HBs) titers, or alanine aminotransferase. HBsAg IC universally declined during follow-up in participants with virologic control or functional cure. Universal declines in HBV RNA and HBcrAg during TDF monotherapy continued with NAP + pegIFN regardless of therapeutic outcome. At the end of therapy, HBV RNA was undetectable in only 5 of 14 participants with functional cure but became undetectable after removal of therapy in all participants with functional cure. Undetectable HBV RNA at the end of therapy in 5 participants was followed by relapse to virologic control or viral rebound. Conclusion: Anti-HBs-independent mechanisms contribute to HBsAg clearance during NAP therapy. Inactivation of cccDNA does not predict functional cure following NAP-based therapy; however, functional cure is accompanied by persistent inactivation of cccDNA. Persistent HBsAg loss with functional cure may also reflect reduction/clearance of integrated HBV DNA. Clinicaltrials.org number NCT02565719." @default.
• W3180625801 created "2021-07-19" @default.
• W3180625801 creator A5004344389 @default.
• W3180625801 creator A5016243200 @default.
• W3180625801 creator A5018691048 @default.
• W3180625801 creator A5026252641 @default.
• W3180625801 creator A5028453121 @default.
• W3180625801 creator A5029504247 @default.
• W3180625801 creator A5032215564 @default.
• W3180625801 creator A5035943094 @default.
• W3180625801 creator A5036117405 @default.
• W3180625801 creator A5046322137 @default.
• W3180625801 creator A5051327660 @default.
• W3180625801 creator A5052601880 @default.
• W3180625801 creator A5054187794 @default.
• W3180625801 creator A5058490885 @default.
• W3180625801 creator A5067076974 @default.
• W3180625801 creator A5078259199 @default.
• W3180625801 creator A5083607331 @default.
• W3180625801 creator A5088042854 @default.
• W3180625801 date "2021-07-10" @default.
• W3180625801 modified "2023-10-18" @default.
• W3180625801 title "Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy" @default.
• W3180625801 cites W1555699566 @default.
• W3180625801 cites W1967633361 @default.
• W3180625801 cites W2022652313 @default.
• W3180625801 cites W2050571266 @default.
• W3180625801 cites W2135719897 @default.
• W3180625801 cites W2138808823 @default.
• W3180625801 cites W2143413072 @default.
• W3180625801 cites W2173007581 @default.
• W3180625801 cites W2199462368 @default.
• W3180625801 cites W2406974152 @default.
• W3180625801 cites W2519620618 @default.
• W3180625801 cites W2544680672 @default.
• W3180625801 cites W2566914683 @default.
• W3180625801 cites W2586854864 @default.
• W3180625801 cites W2611427234 @default.
• W3180625801 cites W2757476358 @default.
• W3180625801 cites W2776483213 @default.
• W3180625801 cites W2779389699 @default.
• W3180625801 cites W2801666689 @default.
• W3180625801 cites W2802499642 @default.
• W3180625801 cites W2804629653 @default.
• W3180625801 cites W2805190163 @default.
• W3180625801 cites W2898189026 @default.
• W3180625801 cites W2900781853 @default.
• W3180625801 cites W2904485024 @default.
• W3180625801 cites W2905891004 @default.
• W3180625801 cites W2915009094 @default.
• W3180625801 cites W2956174697 @default.
• W3180625801 cites W2980521205 @default.
• W3180625801 cites W2988554061 @default.
• W3180625801 cites W3009378833 @default.
• W3180625801 cites W3011016130 @default.
• W3180625801 cites W3031206422 @default.
• W3180625801 cites W3104033816 @default.
• W3180625801 cites W3113225533 @default.
• W3180625801 cites W3127691554 @default.
• W3180625801 doi "https://doi.org/10.1002/hep4.1767" @default.
• W3180625801 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8557319" @default.
• W3180625801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34558823" @default.
• W3180625801 hasPublicationYear "2021" @default.
• W3180625801 type Work @default.
• W3180625801 sameAs 3180625801 @default.
• W3180625801 citedByCount "10" @default.
• W3180625801 countsByYear W31806258012021 @default.
• W3180625801 countsByYear W31806258012022 @default.
• W3180625801 countsByYear W31806258012023 @default.
• W3180625801 crossrefType "journal-article" @default.
• W3180625801 hasAuthorship W3180625801A5004344389 @default.
• W3180625801 hasAuthorship W3180625801A5016243200 @default.
• W3180625801 hasAuthorship W3180625801A5018691048 @default.
• W3180625801 hasAuthorship W3180625801A5026252641 @default.
• W3180625801 hasAuthorship W3180625801A5028453121 @default.
• W3180625801 hasAuthorship W3180625801A5029504247 @default.
• W3180625801 hasAuthorship W3180625801A5032215564 @default.
• W3180625801 hasAuthorship W3180625801A5035943094 @default.
• W3180625801 hasAuthorship W3180625801A5036117405 @default.
• W3180625801 hasAuthorship W3180625801A5046322137 @default.
• W3180625801 hasAuthorship W3180625801A5051327660 @default.
• W3180625801 hasAuthorship W3180625801A5052601880 @default.
• W3180625801 hasAuthorship W3180625801A5054187794 @default.
• W3180625801 hasAuthorship W3180625801A5058490885 @default.
• W3180625801 hasAuthorship W3180625801A5067076974 @default.
• W3180625801 hasAuthorship W3180625801A5078259199 @default.
• W3180625801 hasAuthorship W3180625801A5083607331 @default.
• W3180625801 hasAuthorship W3180625801A5088042854 @default.
• W3180625801 hasBestOaLocation W31806258013 @default.
• W3180625801 hasConcept C126322002 @default.
• W3180625801 hasConcept C159047783 @default.
• W3180625801 hasConcept C159654299 @default.
• W3180625801 hasConcept C189490182 @default.
• W3180625801 hasConcept C203014093 @default.
• W3180625801 hasConcept C2522874641 @default.
• W3180625801 hasConcept C2777382497 @default.
• W3180625801 hasConcept C2777410769 @default.
• W3180625801 hasConcept C2777451964 @default.

• next